Immunic, Inc. is led by Erik Lundgren, who serves as the Chief Executive Officer. He brings extensive biopharmaceutical executive experience spanning global commercial strategy, product launches, and portfolio leadership—having previously held senior leadership roles at Genentech and the Roche Group—to steer the organization through its late-stage clinical development programs. He succeeded Dr. Daniel Vitt, who transitioned to focus on overarching scientific strategy and portfolio advancement while retaining a seat on the company's board of directors.